Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial [0.03%]
长效注射卡博特egravir-利匹韦林在青少年艾滋病患者中的可接受性和耐受性（IMPAACT 2017/MOCHA）：一项多中心、开放标签、非比较性一期/二期试验的48周结果
Elizabeth D Lowenthal,Jennifer Chapman,Kristin Baltrusaitis et al.
Elizabeth D Lowenthal et al.
Background: Long-acting cabotegravir and rilpivirine is the first intramuscular injectable antiretroviral treatment regimen recommended for maintenance of virological suppression in adults living with HIV-1. We report acc...
Mauer Alexandre da Ascensão Gonçalves,Humberto Morais,Pedro Dos Reis Sousa E Almeida et al.
Mauer Alexandre da Ascensão Gonçalves et al.
The Lancet Hiv
The Lancet Hiv
HIV in Sudan's war: a silent emergency amid a protracted conflict [0.03%]
苏丹战争中的艾滋病毒：长期冲突中的一个沉默的紧急情况
Elbushra Ali Mohamed Herieka,Maisoon Abdalla Mohamed Abdelrahman,Nadia Ahmed et al.
Elbushra Ali Mohamed Herieka et al.
Standardisation of monitoring routines for new long-acting antiretrovirals in development [0.03%]
长效抗逆转录病毒药物研发中的监测常规标准化
Christian Hoffmann,Jürgen K Rockstroh
Christian Hoffmann
The US Food and Drug Administration's clinical hold on Gilead Sciences' once-weekly combination of GS-1720 and GS-4182 due to unexpected CD4 T-cell and lymphocyte count declines represents a key safety signal in long-acting HIV therapy deve...
Laith J Abu-Raddad
Laith J Abu-Raddad
HIV prevalence, risk behaviours, and cascade of care among men who have sex with men in Iran: a nationwide, cross-sectional, biobehavioural survey [0.03%]
伊朗男男性行为者中艾滋病病毒感染率、危险行为及治疗依从链的全国性横断面生物-行为调查
Mehrdad Khezri,Soheil Mehmandoost,Fatemeh Tavakoli et al.
Mehrdad Khezri et al.
Background: Men who have sex with men (MSM) in the Middle East and north Africa are often referred to as hard-to-reach because same-sex practices are subject to pervasive stigma, which hinders epidemiological surveillance...
Roger Pebody
Roger Pebody